retatrutide for obesity Phase 2 Trial of is retatrutide available in the
Description
Few and Vol
Lilly is currently testing retatrutide in late-stage trials.
The STEP trials are testing semaglutide at the higher dose of 2.4 mg/week (as compared to 1.0 mg/week for the original diabetes indication), specifically for promoting weight loss, regardless of the presence of type 2 diabetes
Reach us at [email protected] or call (602) 489-4958
Muscle Mass Reduction Studies indicate that up to 40% of weight loss on some GLP-1 medications can actually be lean muscle rather than fat tissue
This leads to steadier energy levels and better metabolic stability (NIH)
